Europe Cancer Biomarkers Market to Grow with a CAGR of 11.0% during the forecast period 2022 to 2029

 

Europe Cancer Biomarkers Market Analysis and Size

Data Bridge Market Research analyses that the cancer biomarkers market which was USD 4.15 billion in 2022, would rocket up to USD 9.56 billion by 2030, and is expected to undergo a CAGR of 11.0% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

In addition, competitor analysis is performed very well in the large scale Europe Cancer Biomarkers Market report which takes into account vital aspects about the key players in the market such as strong and weak points of the competitors and analysis of their strategies with respect to product and market. Such details about competitive landscape plays very important role in deciding about the enrichments required in the product already in the market or the future product. This market report has been framed after thoroughly understanding business environment which best suits the requirements of the client. The top notch Europe Cancer Biomarkers Market business report provides estimations about the growth rate and the market value based on market dynamics and growth inducing factors.

Europe Cancer Biomarkers Market Scope and Segmentation

REPORT METRIC

DETAILS

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015 - 2020)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Product (Consumables, Services, Software, Growth Hormone Therapy), Type (Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers, Protein Biomarkers, Pharmacodynamics Biomarkers, Genetic Biomarkers), Profiling Technologies (OMICS, Imaging Technology, Immunoassays, Cytogenetics and Bioinformatics), Service (Sample Preparation, Assay Development, Biomarkers and Testing), Application (Diagnostics Development, Drug Discovery and Development, Personalized Medicine, Disease-Risk Assessment, Others), Disease (Prostate Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer, Cervical Cancer, and Other Diseases), Indication (Cancer, Cardiovascular Disorders, Neurological Disorders, Immunological Disorders, Others)

Countries Covered

Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe

Market Players Covered

F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Abbott (U.S.), QIAGEN (Germany), PerkinElmer, Inc. (U.S.), Merck KGaA (Germany) , Bio-Rad Laboratories, Inc. (U.S.) , Enzo Biochem, Inc. (U.S), Charles River Laboratories (U.S.), Eurofins Scientific (Luxembourg), Agilent Technologies, Inc. (U.S.), Bruker (U.S.), Siemens (U.S.), Epigenomics AG (Germany), General Electric (U.S.)

Market Opportunities

  • Increased R&D activities
  • Increasing use of biomarker technologies in drug development


Comments

Popular posts from this blog

Gesture Recognition and Touchless Sensing Market Expected to reach a valuation USD 64.19 billion by 2028

Geographic Information System (GIS) Market Industry Key player